ABT-263. Bcl-2 inhibitor, apoptosis inducer, oncolytic

Drugs of the Future

Volumn 33, Issue 10, 2008, Pages 829-837

  Wang, Y ^a   Castaner R ^b   Bolos J ^b  

^a Prous Science ^*  (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; N [4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXENYLMETHYL]PIPERAZIN 1 YL]BENZOYL] 4 [3 (4 MORPHOLINYL) 1 (PHENYLSULFANYLMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONAMIDE; PACLITAXEL; PREDNISOLONE; PROTEIN BCL 2; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; BLEEDING; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; LUNG SMALL CELL CANCER; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PLASMA CLEARANCE; RESPIRATORY FAILURE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; T CELL LYMPHOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR REGRESSION;

EID: 58349104582     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.33.10.1265203     Document Type: Article

References (43)

1. Bruncko, M., Ding, H., Elmore, S.W. et al. (Abbott Laboratories Inc.). Apoptosis promoters. EP 1888550, US 2007027135, US 7390799, WO 2007040650.
2. Ding, H., Park, C.-M., Bruncko, M. et al. ABT-263, an orally bioavailable inhibitor of Bcl-2 family proteins. 235th ACS Natl Meet (April 6-10, New Orleans) 2008, Abst MEDI 110.
3. Zhang, H., Zhou, J., Ha, C., Pei, D., Ding, K. An efficient synthesis of ABT-263, a novel inhibitor of antiapoptotic Bcl-2 proteins. Synthesis 2008, (15): 2398-404.
4. Song, X., Bruncko, M., Ding, H. et al. P2 site SAR development toward ABT-263, an orally bioavailable inhibitor of Bcl-2 family proteins. 235th ACS Natl Meet (April 6-10, New Orleans) 2008, Abst MEDI 78.
5. Letai, A., Bassik, M.C., Walensky, L.D., Sorcinelli, M.D., Weiler, S., Korsmeyer, S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2(3): 183-92.
6. Kuwana, T., Bouchier-Hayes, L., Chipuk, J.E., Bonzon, C., Sullivan, B.A., Green, D.R., Newmeyer, D.D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005, 17(4): 525-35.
7. Certo, M., Del Gaizo, Moore, V., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S.A., Letai, A. Mitochondfia primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9(5): 351-65.
8. Willis, S.N., Fletcher, J.I., Kaufmann, T. et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315(5813): 856-9.
9. Adams, J.M., Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26: 1324-37.
10. Tsujimoto, Y. Role of Bcl-2 family proteins in apoptosis: Apoptosomes or mitochondria? Genes Cells 1998, 3(11): 697-707.
11. Bruncko, M., Oost, T.K., Bell, B.A. et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem 2007, 50(4): 641-62.
12. Chen, S., Dai, Y., Harada, H., Dent, P., Grant, S. Mcl-1 downregulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007, 67(2): 782-91.
13. Kohl, T.M., Hellinger, C., Ahmed, F., Buske, C., Hiddemann, W., Bohlander, S.K., Spiekermann, K. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment medated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007, 21(8): 1763-72.
14. Kang, M.H., Kang, Y.H., Szymanska, B. et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110(6): 2057-66.
15. Tahir, S.K., Yang, X., Anderson, M.G. et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007, 67(3): 1176-83.
16. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435(7042): 677-81.
17. van Delft, M.F., Wei, A.H., Mason, K.D. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2005, 10(5): 389-99.
18. Trudel, S., Stewart, A. K., Li, Z. et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007, 13(2, Pt. 1): 621-9.
19. Kline, M.P., Rajkumar, S.V., Timm, M.M. et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple meyloma cells. Leukemia 2007, 21(7): 1549-60.
20. Del Gaizo Moore, V., Brown, J.R., Certo, M.., Love, T.M.., Novina, C.D., Letai, A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007, 117(1): 112-21.
21. Bruncko, M. ABT-263, an orally bioavailable and efficacious inhibitor of Bcl-2 family proteins. 235th ACS Natl Meet (April 6-10, New Orleans) 2008, Abst MEDI 340.
22. Tse, C., Shoemaker, A.R., Adickes, J. et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68(9): 3421-8.
23. A phase 1/2a study of ABT-263 in subjects with relapsed or refractory chronic lymphocytic leukemia (NCT00481091). ClinicalTrials.gov Web site, October 10, 2008.
24. A phase 1/2a study of ABT-263 in subjects with small cell lung cancer (SCLC) or other non-hematological malignancies (NCT00445198). ClinicalTrials.gov Web site, October 10, 2008.
25. ABT-263 in treating patients with relapsed or refractory lymphoid cancer (NCT00408811). ClinicalTrials.gov Web site, October 10, 2008.
26. A study of ABT-263 in subjects with relapsed or refractory Jymphoid malignancies (NCT00406809). ClinicalTrials.gov Web site, October 10, 2008.
27. Oral bioavailability and pharmacokinetics (PK) study of the capsule formulation of ABT-263 in cancer (NCT00743028). ClinicalTrials.gov Web site, October 10, 2008.
28. Shoemaker, A.R., Mitten, MJ, Adickes, J. et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008, 14(11): 3268-77.
29. Lock, R., Carol, H., Houghton, P.J. et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50(6): 1181-9.
30. Gandhi, L., Camidge, D.R., Khaira, D. et al. An ongoing phase 1 study of ABT-263 in patients with relapsed small cell lung cancer and other solid tumors. Ann Oncol [33rd Eur Soc Med Oncol (ESMO) Congr (Sept 12-16, Stockholm) 2008]2008, 19(Suppl. 8): Abst 324P.
31. Brown, J., Roberts, A., Seymour, J.F. et al. ngoing phase 1 studies of ABT-263; pharmacokinetics, safety and anti-tumor activity in patients with relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Ann Oncol [33rd Eur Soc Med Oncol (ESMO) Congr (Sept 12-16, Stockholm) 2008] 2008, 19(Suppl. 8): Abst 729PD.
32. Tse, C., Zhang, H., Chen, J. et al. The Bcl-2 family protein inhibitor, ABT-263, promotes apoptotic-like response in isolated platelets. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 1122.
33. Shoemaker, A.R., Mitten, M.J., Adickes, J. et al. The Bcl-2 family inhibitor ABT-263 shows significant but reversible thrombocytopenia in mice. Blood (48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 1107.
34. Elmore, S.W., Bauch, J., Fryer, R. M. et al. Bcl-2 family protein inhibitors induce a unique thrombocytopenia in vivo. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 4236.
35. O'Connor, O., Czuczman, M.S., LaCasce, A. et al. A phase 1 study evaluating the safety, PK & efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Ann Oncol [33rd Eur Soc Med Oncol (ESMO) Congr (Sept 12-16, Stockholm) 2008] 2008, 19(Suppl. 8): Abst 101.
36. Wilson, W.H., Czuczman, M.S., LaCasce, A.S. et al. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 8511.
37. Wilson, W.H., Tulpule, A., Levine, A.M. et al. A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007]2007, 110(11): Abst 1371.
38. Smith, M.A., Maris, J.M., Keir, S.T. et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the Bcl-2 inhibitor ABT-263. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 4951.
39. Zhang, H., Chen, J., Chen, Z. et al. The Bcl-2 family protein inhibitor, ABT-263, broadly potentiates the cytotoxicity of other therapeutic agents in vitro. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 726.
40. Elmore, S. ABT-263. An orally bioavailable small molecule inhibitor to Bcl-2 family proteins. Eur J Cancer Suppi [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 200612006, 4(12): Abst 466.
41. Roberts, A., Gandhi, L., O'Connor, O.A. et al. Reduction in platelet counts as a mechanistic bibmarker and guide for adaptive dose-escalation in phase/studies of the Bcl-2 family inhibitor ABT-263. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 3542.
42. Shoemaker, A.R., Mitten, M.J., Oleksijew, A. et al. The Bcl-2 family inhibitor ABT-263 shows significant anti-tumor efficacy in models of B cell non-Hodgkin's lymphoma. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006,108(l 1): Abst 825.
43. Shoemaker, A.R., Oleksijew, A., Mitten, M.J. et al. Preclinical activity of the Bcl-2 family inhibitor ABT-263 in models of small cell lung cancer. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 4953.